Precision Signals
Precision Signals
Podcast Description
Precision Signals is a podcast from the CEO Roundtable on Cancer about decoding biomedical progress: what’s real, what matters, and what’s next. We talk with scientists, regulators, investors, and builders operating across the messy interface of research, healthcare, and policy. Some are moving the system from within; others are reshaping it from the outside. All of them bring signal in a world crowded with noise.
Podcast Insights
Content Themes
The podcast covers critical topics related to biomedical research, healthcare systems, and regulatory frameworks. Episodes like 'The Mission is the Boss' focus on the challenges in clinical trials, discussing the journey of innovators like Dr. Michelle Longmire, while another episode, 'AI in Oncology: Hype, Evidence, and the Threshold of Clinical Trust', dives into the critical necessity of randomized trials for AI adoption in cancer care, illustrating the intricate balance between innovation and practical application.
Precision Signals is a podcast from the CEO Roundtable on Cancer about decoding biomedical progress: what’s real, what matters, and what’s next. We talk with scientists, regulators, investors, and builders operating across the messy interface of research, healthcare, and policy. Some are moving the system from within; others are reshaping it from the outside. All of them bring signal in a world crowded with noise.
Sunil Verma, SVP and Global Head of Oncology at AstraZeneca, has lived a life defined by reinvention. Born in Zambia, raised across Africa, India, and Canada, he was accepted to medical school at 19, became one of the most respected breast cancer oncologists in Canada, built a cancer center in Calgary from the ground up, and then left academia entirely to help write the next chapters of oncology at AstraZeneca alongside the late Jose Baselga.
In this conversation, Sean Khozin and Sunil explore the formative experiences that shaped his worldview and leadership philosophy, what it means to build healthcare infrastructure around the concept of healing, and how AstraZeneca’s oncology portfolio expanded from a single asset into one of the most consequential in the world.
They go deep on the science and strategy behind antibody-drug conjugates (ADCs), the frontier of ADC and immunotherapy combinations, and a distinction Sunil considers the true next frontier of the field: the difference between precision medicine and genuinely personalized medicine, where patient values are matched to therapeutic value.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.